



JAN 25 2006

Please type a plus sign (+) inside this box →

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/964,065
				Filing Date	September 26, 2001
				First Named Inventor	KOVESDI, Imre
				Group Art Unit	4636 1633
				Examiner Name	PRIEBE, Scott David
Sheet	1	of	3	Attorney Docket Number	213257

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
SP	CG	US- 4,497,796		02-05-1985	Salser et al.	
	CH	US- 4,727,028		02-23-1988	Santerre et al.	
	CI	US- 4,740,463		04-26-1988	Weinberg et al.	
	CJ	US- 5,190,931		03-02-1993	Inouye	
	CK	US- 5,208,149		05-04-1993	Inouye	
	CL	US- 5,518,913		05-21-1996	Massie et al.	
	CM	US- 6,040,174		03-21-2000	Imler et al.	
	CN	US- 6,127,175		10-03-2000	Vigne et al.	
↓	CO	US- 6,133,028		10-17-2000	Imler et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Check if Translation Provided**
		Office	Number	Kind Code				
SP	CP	AU	95/28533		03-21-1996	Introgene B.V.		<input type="checkbox"/>
	CQ	CA	2,053,187	A1	04-11-1993	Natl. Res. Council		<input type="checkbox"/>
	CR	WO	94/24297	A	10-27-1994	Rhone-Poulenc Rorer		<input checked="" type="checkbox"/>
	CS	WO	94/26914	A	11-24-1994	Rhone-Poulenc Rorer		<input checked="" type="checkbox"/>
	CT	WO	95/16772	A	06-22-1995	Cornell Res. Found.		<input type="checkbox"/>
	CU	WO	96/13596	A	05-09-1996	Rhone-Poulenc Rorer		<input checked="" type="checkbox"/>
	CV	WO	96/18418	A	06-20-1996	Genetic Therapy, Inc.		<input type="checkbox"/>
↓	CW	WO	96/22378	A	07-25-1996	Rhone-Poulenc Rorer		<input checked="" type="checkbox"/>

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/964,065
				Filing Date	September 26, 2001
				First Named Inventor	KOVESDI, Imre
				Group Art Unit	1636 1633
				Examiner Name	PRIEBE, Scott David
Sheet	2	of	3	Attorney Docket Number	213257

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Check if Translation Provided**	
SP	CX	BROUGH et al., "A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4," <i>J. Virol.</i> , 70 (9), 6497-6501 (1996).	<input type="checkbox"/>	
	CY	BRUNET et al., "Concentration dependence of transcriptional transactivation in inducible E1A-containing human cells," <i>Mol. Cell. Biol.</i> , 8 (11), 4799-4807 (November 1988).	<input type="checkbox"/>	
	CZ	BYRD et al., "Malignant transformation of human embryo retinoblasts by cloned adenovirus 12 DNA," <i>Nature</i> , 298 (5869), 69-71 (July 1, 1982).	<input type="checkbox"/>	
	DA	CRYSTAL et al., "Administration of an adenovirus containing the human <i>CFTR</i> cDNA to the respiratory tract of individuals with cystic fibrosis," <i>Nature Genet.</i> , 8, 42-51 (1994).	<input type="checkbox"/>	
	DB	GALLIMORE et al., "Properties of rat cells transformed by DNA plasmids containing adenovirus type 12 E1 DNA or specific fragments of the E1 region: comparison of transforming frequencies," <i>Cancer Res.</i> , 45 (6), 2670-2680 (June 1985).	<input type="checkbox"/>	
	DC	GRODZICKER et al., "Expression of unselected adenovirus genes in human-cells co-transformed with the HSV-1-TK gene and adenovirus 2 DNA," <i>Cell</i> , 21 (2), 453-463 (September 1980).	<input type="checkbox"/>	
	DD	KETNER et al., "Complementation of adenovirus E4 mutants by transient expression of E4 cDNA and deletion plasmids," <i>Nucl. Acids Res.</i> , 17 (8), 3037-3048 (April 25, 1989).	<input type="checkbox"/>	
↓	DE	KLINMAN, "Introduction to the issues: Viral vectors and potential problems in their use," <i>Developments in Biological Standardization</i> , 76, 299-300 (S. Karger AG, Basel, Switzerland, 1992).	<input type="checkbox"/>	

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Please type a plus sign (+) inside this box → +

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/964,065
				Filing Date	September 26, 2001
				First Named Inventor	KOVESDI, Imre
				Group Art Unit	1636 1633
				Examiner Name	PRIEBE, Scott David
Sheet	3	of	3	Attorney Docket Number	213257

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		Check if Translation Provided ²
SP	DF	LEWIS et al., "Viral messenger RNA in six lines of adenovirus-transformed cells," <i>Virology</i> , 115 (2), 345-360 (December 1981).		<input type="checkbox"/>
	DG	ROBERTS et al., "Individual adenovirus type 5 early region 1A gene products elicit distinct alterations of cellular morphology and gene expression," <i>J. Virol.</i> , 56 (2), 404-413 (November 1985).		<input type="checkbox"/>
	DH	WANG et al., "Second-generation adenovirus vectors," <i>Nature Med.</i> , 2 (6), 714-716 (1996).		<input type="checkbox"/>
	DI	YANG et al., "Inactivation of <i>E2a</i> in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis," <i>Nature Gen.</i> , 7, 362-369 (1994).		<input type="checkbox"/>
↓	DJ	ZHOU et al., "Progress towards development of an adenoviral vector with deletions of E1 and E2a," <i>J. Cell. Biochem., Supp.</i> 21A, 434 (1995).		<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	/Scott Priebe/	Date Considered	07/25/2006
--------------------	----------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.